PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
35.81%
Positive EBIT growth while AVXL is negative. John Neff might see a substantial edge in operational management.
36.41%
Positive operating income growth while AVXL is negative. John Neff might view this as a competitive edge in operations.
439.57%
Positive net income growth while AVXL is negative. John Neff might see a big relative performance advantage.
440.81%
Positive EPS growth while AVXL is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
440.81%
Positive diluted EPS growth while AVXL is negative. John Neff might view this as a strong relative advantage in controlling dilution.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
681.03%
Positive OCF growth while AVXL is negative. John Neff would see this as a clear operational advantage vs. the competitor.
681.03%
Positive FCF growth while AVXL is negative. John Neff would see a strong competitive edge in net cash generation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
1209.68%
Positive long-term OCF/share growth while AVXL is negative. John Neff would see a structural advantage in sustained cash generation.
1209.68%
Positive OCF/share growth while AVXL is negative. John Neff might see a comparative advantage in operational cash viability.
1209.68%
Positive 3Y OCF/share CAGR while AVXL is negative. John Neff might see a big short-term edge in operational efficiency.
934.70%
Positive 10Y CAGR while AVXL is negative. John Neff might see a substantial advantage in bottom-line trajectory.
934.70%
Positive 5Y CAGR while AVXL is negative. John Neff might view this as a strong mid-term relative advantage.
934.70%
Positive short-term CAGR while AVXL is negative. John Neff would see a clear advantage in near-term profit trajectory.
-244.00%
Negative equity/share CAGR over 10 years while AVXL stands at 0.00%. Joel Greenblatt sees a fundamental red flag unless the competitor also struggles.
-244.00%
Negative 5Y equity/share growth while AVXL is at 0.00%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
-244.00%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
2826.88%
Asset growth above 1.5x AVXL's 215.28%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
26.94%
Positive BV/share change while AVXL is negative. John Neff sees a clear edge over a competitor losing equity.
3.22%
Debt shrinking faster vs. AVXL's 40.28%. David Dodd sees a safer balance sheet if it doesn't impair future growth.
No Data
No Data available this quarter, please select a different quarter.
-10.82%
We cut SG&A while AVXL invests at 8.09%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.